Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate-to-Severe Plaque Psoriasis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05283135
What this trial is testing

High Dose Risankizumab for Psoriasis

Who this might be right for
Psoriasis
Oregon Medical Research Center 20
Not applicableStudy completedNCT05388916
What this trial is testing

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Who this might be right for
Moderate to Severe Chronic Plaque Psoriasis
Novartis Pharmaceuticals 42
Testing effectiveness (Phase 2)Study completedNCT00669916
What this trial is testing

A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Study completedNCT01001468
What this trial is testing

Study to Assess VB-201 in Patients With Psoriasis

Who this might be right for
Active Plaque Psoriasis
Vascular Biogenics Ltd. operating as VBL Therapeutics 185
Large-scale testing (Phase 3)Study completedNCT03598790
What this trial is testing

Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Chronic Plaque PsoriasisModerate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL 1,353
Post-approval studies (Phase 4)Study completedNCT02749370
What this trial is testing

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

Who this might be right for
Plaque Psoriasis
Amgen 80
Large-scale testing (Phase 3)Active Not RecruitingNCT03997786
What this trial is testing

Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Who this might be right for
Moderate-to-severe Chronic Plaque Psoriasis
Sun Pharmaceutical Industries Limited 135
Large-scale testing (Phase 3)Not Yet RecruitingNCT07432854
What this trial is testing

A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

Who this might be right for
Moderate to Severe Plaque Psoriasis
Dermavon Holdings Limited 540
Testing effectiveness (Phase 2)Study completedNCT04102241
What this trial is testing

Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Tianjin Hemay Pharmaceutical Co., Ltd 216
Large-scale testing (Phase 3)Study completedNCT04175613
What this trial is testing

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Amgen 160
Large-scale testing (Phase 3)Not Yet RecruitingNCT06643260
What this trial is testing

Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

Who this might be right for
Plaque Psoriasis
Can-Fite BioPharma 705
Large-scale testing (Phase 3)Ended earlyNCT01708590
What this trial is testing

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

Who this might be right for
Psoriasis
Bausch Health Americas, Inc. 661
Testing effectiveness (Phase 2)Looking for participantsNCT07489885
What this trial is testing

Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
InventisBio Co., Ltd 75
Testing effectiveness (Phase 2)Study completedNCT01154101
What this trial is testing

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

Who this might be right for
Psoriasis
Sirtris, a GSK Company 40
Post-approval studies (Phase 4)Study completedNCT02690701
What this trial is testing

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Chronic Plaque Psoriasis
Novartis Pharmaceuticals 91
Not applicableUnknownNCT05144165
What this trial is testing

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Who this might be right for
PsoriasisPsoriasis PalmarisPsoriasis Inverse+8 more
Centre of Evidence of the French Society of Dermatology 30
Not applicableStudy completedNCT01076192
What this trial is testing

Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

Who this might be right for
Moderate-to-severe Chronic Plaque Psoriasis
AbbVie (prior sponsor, Abbott) 547
Large-scale testing (Phase 3)Study completedNCT05975268
What this trial is testing

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Moderate to Severe Chronic Plaque Psoriasis
Shanghai Junshi Bioscience Co., Ltd. 747
Large-scale testing (Phase 3)Study completedNCT02672852
What this trial is testing

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Who this might be right for
Psoriasis
AbbVie 507
Large-scale testing (Phase 3)Study completedNCT04595409
What this trial is testing

Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Bioeq GmbH 392
Next Page